Azitra (AZTR) Depreciation & Amortization (CF) (2022 - 2026)
Azitra's (AZTR) quarterly Depreciation & Amortization (CF) came in at $37692.0 in Q1 2026, up 10.68% YoY from $34055.0 in Q1 2025, and up 7.66% on a QoQ basis from $35010.0 in Q4 2025.
Azitra (AZTR) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Depreciation & Amortization (CF) data on file, last reported at $37692.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 10.68% year-over-year to $37692.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $141706.0 (up 6.71% YoY) and the FY2025 annual result came in at $138069.0, up 5.25% from the prior year.
- Depreciation & Amortization (CF) grew to $37692.0 in Q1 2026, from $35010.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $37692.0 in Q1 2026 to a low of $30148.0 in Q2 2022.
- A 5-year average of $33201.1 and a median of $32620.5 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) slipped 0.46% — and 2026, when it gained 10.68%.
- Tracing AZTR's Depreciation & Amortization (CF) over 5 years: stood at $32370.0 in 2022, then dropped by 0.33% to $32263.0 in 2023, then gained by 3.02% to $33238.0 in 2024, then increased by 5.33% to $35010.0 in 2025, then rose by 7.66% to $37692.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $37692.0 (Q1 2026), $35010.0 (Q4 2025), and $34766.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | 38,793.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38,793.00 |
| Jun 30, 2026 | 38,793.00 |
| Mar 31, 2026 | 37,692.00 |
| Mar 31, 2026 | 37,692.00 |
| Dec 31, 2025 | 35,010.00 |
| Dec 31, 2025 | 35,010.00 |
| Sep 30, 2025 | 34,766.00 |
| Sep 30, 2025 | 34,766.00 |
| Jun 30, 2025 | 34,238.00 |
| Jun 30, 2025 | 34,238.00 |
| Mar 31, 2025 | 34,055.00 |
| Mar 31, 2025 | 34,055.00 |
| Dec 31, 2024 | 33,238.00 |
| Dec 31, 2024 | 33,238.00 |
| Sep 30, 2024 | 32,997.00 |
| Sep 30, 2024 | 32,997.00 |
| Jun 30, 2024 | 32,507.00 |
| Jun 30, 2024 | 32,507.00 |
| Mar 31, 2024 | 32,446.00 |
| Mar 31, 2024 | 32,446.00 |